Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its ...

Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...

During the first day of the 44 th Annual JP Morgan Healthcare Conference in San Francisco, a clear narrative emerged. With ...

NICE has recommended Tysabri and biosimilar Tyruko as an option for patients with highly active relapsing-remitting multiple ...

Biogen CEO Chris Viehbacher joins 'Squawk Box' to discuss the company's 2026 outlook, drug pipeline, the focus on rare ...

Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all ...

Biogen and Eisai recently announced that Chinese regulators have accepted their Biologics License Application for a subcutaneous, at‑home injectable version of Alzheimer’s drug LEQEMBI, advancing it ...

The US Food and Drug Administration (FDA) has rejected Biogen’s high-dose Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA). The agency chose to decline the antisense ...

Biogen and Alkermes won approval Oct. 30 for their new multiple sclerosis drug, Vumerity, according to The Boston Globe. Vumerity is an oral drug designed to treat relapsing forms of MS, a chronic ...

Investing.com -- Biogen Inc. ’s new at-home Alzheimer’s drug will provide an advantage over Eli Lilly Co. ’s competing ...

Biogen BIIB announced that the European Commission (“EC”) has approved Zurzuvae (zuranolone) to treat postpartum depression (PPD) in adults after childbirth. Following this approval, Zurzuvae became ...